In the Q3, Becton Dickinson And Company's corporate clients experienced a fall by -29.45 % in their costs of revenue, compared to a year ago, sequentially costs of revenue grew by 5.58 %. During the corresponding time, Becton Dickinson And Company recorded a revenue increase by 5.44 % year on year, sequentially revenue grew by 5.71 %. While revenue at the Becton Dickinson And Company's corporate clients fell by -18.75 % year on year, sequentially revenue grew by 7.06 %.
Customers of Becton Dickinson And Company saw their costs of revenue fall by -29.45 % in Q3 compare to a year ago, sequentially costs of revenue grew by 5.58 %, for the same period Becton Dickinson And Company recorded revenue increase by 5.44 % year on year, sequentially revenue grew by 5.71 %.
Becton Dickinson's Comment on Sales, Marketing and Customers
The company sells products to researchers at pharmaceutical and biotechnology companies, academic institutions, government laboratories, and private foundations. Its customers include organizations reliant on grants from U.S. government agencies such as the National Institutes of Health and comparable agencies in other countries. The company faces market challenges from government mechanisms that control healthcare expenditures, including competitive bidding, tenders, price regulation programs like volume-based procurement (VoBP), payback provisions, and changes in reimbursement policies. Research and development spending by customers can fluctuate due to economic conditions and government funding levels, which have decreased in fiscal year 2025. The company’s future growth depends on new product development, which requires significant investment and regulatory approvals and is subject to risks such as patent issues and market acceptance. Uncertainties in government funding and economic factors, including potential federal government shutdowns, may adversely affect the business.
Becton Dickinson’s Comment on Sales, Marketing and Customers
The company sells products to researchers at pharmaceutical and biotechnology companies, academic institutions, government laboratories, and private foundations. Its customers include organizations reliant on grants from U.S. government agencies such as the National Institutes of Health and comparable agencies in other countries. The company faces market challenges from government mechanisms that control healthcare expenditures, including competitive bidding, tenders, price regulation programs like volume-based procurement (VoBP), payback provisions, and changes in reimbursement policies. Research and development spending by customers can fluctuate due to economic conditions and government funding levels, which have decreased in fiscal year 2025. The company’s future growth depends on new product development, which requires significant investment and regulatory approvals and is subject to risks such as patent issues and market acceptance. Uncertainties in government funding and economic factors, including potential federal government shutdowns, may adversely affect the business.
Sources:
Becton Dickinson And Company’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Becton Dickinson And Company’s corporate clients.
For your research, we’ve provided 9 tables on Becton Dickinson And Company corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
98.7 %
23.2 %